# A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)

> **NCT02797522** · PHASE1 · TERMINATED · sponsor: **Arrowhead Pharmaceuticals** · enrollment: 47 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** ARC-521 Injection
- **OTHER:** Placebo
- **DRUG:** antihistamine
- **DRUG:** acetaminophen
- **DRUG:** entecavir
- **DRUG:** tenofovir

## Key facts

- **NCT ID:** NCT02797522
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Company decision to discontinue trial
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02797522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02797522, "A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT02797522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*